New Pharma Company Targets Obesity Market Competition

Eli Lilly (NYSE: LLY) is the world’s most valuable healthcare stock, valued at over $760 billion, largely due to its successful GLP-1 products, Mounjaro and Zepbound. The company’s potential to reach a $1 trillion valuation hinges on its continued success in the GLP-1 market, where it faces increasing competition, notably from Roche Holding (OTC: RHHBY).

Want More Context? 🔎